Penfluridol in chronic schizophrenia.
Twenty-eight male chronic schizophrenic patients completed a 6 month treatment with a single weekly dose of 20 to 120 mg penfluridol, a new long- acting oral neuroleptic. Twenty-four patients showed significant improvement at the end of the trial period. Significant reduction in scores could be demonstrated in 21 out of 26 symptom variables. Central side-effects, reported by 19 patients, were mild and transient except in one patient who was withdrawn from the trial. Laboratory investigations and vital signs remained within normal limits.
D000328:Adult; D002908:Chronic Disease; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D008875:Middle Aged; D010395:Penfluridol / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
D010880:Piperidines; D010395:Penfluridol